Primary and secondary pseudo-stability and progression after atezolizumab with and without bevacizumab.

J Immunother Cancer · 2026 · PMC12815109 · PMID 41545308

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The OS HR for HCC patients with mPR demonstrated a trend towards improved survival but did not reach statistical significance, likely due to the small number of individuals with imPR pseudo-stability/progression in this cancer type ( figure 5 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.